Okogen Receives CDSCO Authorization to Advance the EMERALD Phase 1/2 Study of Treyegen™ (OKG-0303) for Acute Infectious Conjunctivitis
October 6, 2026
Clinical Program Represents an Important Step in Validating Okogen’s Host-Directed Antiviral Platform PLANO, Texas — October 6, 2026 Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control
